Advanced Cell Diagnostics "in situ hybridization technology achieved two important milestones

Advanced Cell Diagnostics "in situ hybridization technology achieved two important milestones -

Advanced Cell Diagnostics Inc. (ACD), a leader in the field of molecular pathology and developer of cells and tissue-based analysis tools, announced that its RNAscope ^® RNA in situ hybridization technology has reached two important milestones. in just three years more than 100 peer reviewed articles featuring technology have been published, and with the significant increase in the use of RNAscope, ACD has now built a library of more than 4000 target probes for many species. the probes are designed to operate in less than two weeks, and in just six months, the library has increased over 1500, reflecting the great interest in the advanced technology of the ACD.

Expression Gli1 and ApoE mRNA in the brains of mice FFPE tissue using RNAscope® 2-plex chromogenic reagent kit

RNAscope only has the sensitivity to allow researchers to detect in situ single RNA molecules and provide a quantitative analysis of gene expression at the single cell level. In addition, the technology provides a context showing morphological and spatial specific expression in the cell, while maintaining tissue architecture. RNAscope ability to unlock the full potential of RNA biomarkers, as well as its highly reproducible and easy to use technology, resulting in an average of more than 6 items per month published to date in 2014 - a rate that doubles every year. Now widely used throughout academia and industry, newspapers range from basic research in developmental biology, neuroscience and stem cells in clinical research, such as cancer biomarkers, infectious diseases and ophthalmology in reputable journals such as Nature, Science, Cell, PLoS One, PNAS and Clinical Cancer Research.

localization and quantification of RNA sequences in the context of cells and tissue is a fundamental approach to molecular biology. RNAscope makes accessible to researchers of all levels of experience, as Alexey Pronin, PhD of the University of Miami School of Medicine, which recently published in the journal PLoS One, explained. "Even though I had no previous experience of in situ hybridization assay RNAscope was easy to make and worked first time, which allows us to confirm the expression of three different genes in the eye the mice that we had previously identified via transcriptomics. Importantly, the multiplex test showed that two genes are expressed in two layers of cells separated from the blood vessels of the eyes -. The information that would be difficult to achieve using other technology "

" Publications of our customers are particularly exciting because it shows the validation and adoption of our technologies increasingly at the forefront of scientific research, "said Xiao-Jun Ma, the CSO of the ACD. "And with our 240% growth sensor catalog in the last year, targeting more than 4,000 genes in many species, it is a true testament to the demand for our technology, our time of rapid probe development and scalability of our platform. Together, these two steps are complete validation of the effectiveness of RNAscope technology. in this age of single cell transcriptome RNA in situ hybridization will prove essential in the effort to characterize many newly discovered genes, particularly the vast repertoire of genes non-coding RNA. We believe that the specific advantages of RNAscope technology will undoubtedly speed up the translation of genomic discoveries to clinical medicine, including new products therapeutic and diagnostic. "

For more information on published research on RNAscope, please visit www.acdbio.com /milestoneJuly2014.

about advanced Diagnostics cell, Inc. (ACD)

Advanced cell Diagnostics, Inc. (ACD) is a leader in the emerging field of molecular pathology, developing research tools based on cell and tissue for all areas of biomedical research, and diagnostic testing for personalized medicine. The company's products and services are based on its proprietary RNAscope ^® technology, the most sensitive method for RNA in situ hybridization, and the first quantitative platform for fully automated multiplex fluorescent and chromogenic RNA analysis biomarker. ACD partners with pharmaceutical and biotechnology companies to validate biomarkers for targeted therapy development in cancer and other diseases. These partnerships are the basis for the ACD to develop companion diagnostic tests in conjunction with targeted therapies partners. ACD also pursues internal programs to develop proprietary diagnostic tests in cancer management. Learn more about ACD and RNAscope ^® Technology at www.acdbio.com.